<?xml version="1.0" encoding="UTF-8"?>
<p>The government of South Africa first issued a compulsory license in 1998 after the TRIPS agreement came into effect. HIV infected 15% of all South Africans and the HIV prevalence among its adult population was as high as 20%, among the highest in the world [
 <xref ref-type="bibr" rid="CR11">11</xref>]. In response to the severe epidemic, South Africa passed the 
 <italic>South Africa Medicines and Related Substances Act</italic> in December 1997, authorizing the government to issue a compulsory license and parallel importation. In February 1998, a South African pharmaceutical group united 40 companies who, together, filed a lawsuit on the claim that the 
 <italic>South Africa Medicines and Related Substances Act</italic> of 1997 is unconstitutional because it gives the Minister of Public Health the power to ignore the Patent Act. Ultimately, these companies faced an ethical dilemma of protecting patents over saving human lives and finally withdrew the lawsuit and substantially reduced the price of the drugs. In response, the multinational pharmaceutical companies pressured their own governments asking them to amend the TRIPS Agreement. This action resulted in the Doha Declaration on the TRIPS Agreement and the protocol amending TRIPS [
 <xref ref-type="bibr" rid="CR12">12</xref>].
</p>
